argenx SE (NASDAQ:ARGX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of argenx SE (NASDAQ:ARGX) have been given an average rating of “Moderate Buy” by the twenty-two analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eighteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $658.39.

Several equities research analysts recently commented on ARGX shares. Truist Financial reaffirmed a “buy” rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Wolfe Research upgraded argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target on the stock in a report on Tuesday, November 12th. Guggenheim boosted their price target on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Wedbush restated an “outperform” rating and set a $655.00 price objective on shares of argenx in a research report on Tuesday, December 3rd. Finally, Evercore ISI boosted their target price on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st.

argenx Trading Down 0.0 %

Shares of NASDAQ ARGX opened at $646.45 on Tuesday. The company has a 50-day moving average of $637.69 and a 200 day moving average of $578.86. argenx has a 12-month low of $349.86 and a 12-month high of $678.21. The stock has a market cap of $39.28 billion, a PE ratio of -734.60 and a beta of 0.58.

Hedge Funds Weigh In On argenx

Several institutional investors have recently bought and sold shares of ARGX. FMR LLC boosted its stake in shares of argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the period. Lord Abbett & CO. LLC acquired a new stake in argenx during the 3rd quarter worth approximately $88,339,000. Allspring Global Investments Holdings LLC boosted its position in argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after buying an additional 143,834 shares during the period. Raymond James Financial Inc. acquired a new position in shares of argenx in the fourth quarter worth $43,543,000. Finally, Jennison Associates LLC increased its position in shares of argenx by 27.0% during the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock worth $185,821,000 after acquiring an additional 64,183 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.